Compare STMicroelectronics NV (STM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs GeneDx Holdings Corp — how do they compare? STMicroelectronics NV trades at $52.06 (market cap $48.14B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: STMicroelectronics NV is far larger — about 23.8× GeneDx Holdings Corp's market cap, and STMicroelectronics NV pays a 0.68% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold STMicroelectronics NV for 64 Days and GeneDx Holdings Corp for 19 Days on average.
| STM | WGS | |
|---|---|---|
Market Cap | $48.14B | $2.02B |
Volume | 9,776,015 | 734,640 |
Sector | Technology | Health |
52-Week High | $79.91 | $167.51 |
52-Week Low | $21.20 | $34.51 |
Typical Hold Time | 64 Days | 19 Days |
Enterprise Value | $45.66B | $2.05B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM (STMicroelectronics) is trading at $52.71, down 6.18% over the past 24 hours amid a broader tech selloff. The stock shows mixed signals with a bearish technical outlook but positive analyst sentiment, including a consensus price target of $77.31. Recent financials reveal declining revenue and negative net income margins, though strong cash flow and a solid balance sheet provide stability. Key developments include growing AI data-center revenue projections and new product launches in automotive sensing.
The outlook for STM hinges on execution in AI and automotive segments, with potential upside from analyst targets. Risks include margin pressure from fab transitions and macroeconomic volatility. Investors should weigh strong institutional support against near-term profitability challenges.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
